All Industries

Top Therapeutics Companies

205 Therapeutics companies, sorted by total funding raised.

Gate Bioscience

Biotechnology company developing oral small-molecule ‘molecular gates’ to eliminate disease-causi...

California, United States11–50Biotech, Drug Discovery
Series B·$125.0M·Nov 2025
OnCusp Therapeutics

Clinical-stage biopharma developing targeted oncology therapeutics and ADCs to advance treatments...

Princeton, United States11–50Biotech, Healthcare
Series A·$125.0M·Jan 2024
Epic Bio

Epic Bio (now Epicrispr Biotechnologies) develops epigenetic gene therapies using ultracompact CR...

South San Francisco, United States11–50Biotech, Therapeutics
Series B·$123.0M·Mar 2025
MetacrineIPO

Metacrine is a biotech company developing innovative therapeutics for liver, gastrointestinal, an...

San Diego, United States11–50Biotech, Therapeutics
Series C·$123.0M·Jun 2018
Ouro Medicines

Biotechnology company dedicated to developing immune reset therapeutics for people living with ch...

USA, United States11–50Biotech, Immunology
Series A·$120.0M·Jan 2025
Shinobi Therapeutics

Develops immune-evasive iPSC-derived off-the-shelf cell therapies for cancer and autoimmune disea...

San Diego, United States11–50Biotech, Therapeutics
Extension Round·$119.0M·Aug 2024
GenEdit

GenEdit is revolutionizing gene therapy and gene editing with its nanoparticle delivery technology.

South San Francisco, United States51–200Biotech, Therapeutics
Series B·$118.5M·Feb 2026
Nkarta TherapeuticsIPO

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural ...

South San Francisco, United States51–200Biotech, Oncology
Series B·$114.0M·Sep 2019
Myricx Bio

Biotech company focused on cell and gene therapy development.

London, United Kingdom1–10Biotech, Therapeutics
Venture Round·$113.0M·Jul 2024
Dyno Therapeutics

Biotechnology company applying artificial intelligence to design novel AAV vectors for gene thera...

Cambridge, United States51–200Artificial Intelligence, Biotech
Series A·$109.0M·May 2021
Click Therapeutics

Digital therapeutics and behavioral health company using software as medicine.

New York, United States51–200Digital Health, Therapeutics
Series D·$102.0M·Apr 2026
Catalyst BiosciencesAcquired

Biopharmaceutical company focused on drugs to treat CNS disorders by targeting neuronal nicotinic...

South San Francisco, United States11–50Biotech, Therapeutics
Corporate Round·$100.4M·Jan 2011
NightstarAcquired

Private biopharmaceutical company focused on the development of therapies for retinal dystrophies.

Oxford, United Kingdom51–200Biotech, Healthcare
Series C·$99.1M·Jun 2017
IconOVir Bio

Preclinical-stage biotech developing next-generation oncolytic virus therapies for solid tumors.

San Diego, United States11–50Biotech, Drug Discovery
Venture Round·$97.2M·Jun 2024
Orbis Medicines

Orbis Medicines is pioneering a new era for oral macrocycle drug discovery.

Copenhagen, Denmark11–50Biotech, Drug Discovery
Series B·$93.0M·Jan 2025
Maxion Therapeutics

Biotech developing antibody-based KnotBody therapeutics targeting ion channels and GPCRs to treat...

Cambridge, United Kingdom11–50Life Sciences, Biotech
Series A·$88.0M·Mar 2025
Amicus TherapeuticsIPO

Oral pharmacological chaperone protein therapies to address diseases that result from protein mis...

Cranbury, United States501–1000Biotech, Drug Discovery
Venture Round·$86.0M·Jan 2006
Code Biotherapeutics

A next-generation gene therapy company pioneering the development of targeted non-viral gene ther...

Hatfield, United States11–50Biotech, Therapeutics
Series A·$85.0M·Jun 2022
Tempest TherapeuticsIPO

A clinical-stage oncology company advancing small molecules that combine both targeted and immune...

Brisbane, United States11–50Biotech, Drug Discovery
Private Equity·$85.0M·Apr 2022
Kala PharmaceuticalsIPO

Clinical-stage biopharma developing topical nanoparticle therapies for eye diseases, including tr...

Waltham, United StatesBiotech, Healthcare
Venture Round·$79.5M·Apr 2016
Cure Genetics

Cure Genetics is a Chinese biotech company developing AAV-based gene therapy vectors in partnersh...

Suzhou, China11–50Biotech, Therapeutics
Series B·$77.0M·Jan 2022
Excision BioTherapeutics

Developing CRISPR-based therapies to cure viral infectious diseases.

San Francisco, United States11–50Biotech, Genomics
Grant·$76.8M·Sep 2022
ARS PharmaceuticalsIPO

Develops and commercializes neffy, an FDA-approved needle-free epinephrine nasal spray for treati...

San Diego, United States51–200Healthcare, Therapeutics
Series D·$75.0M·Aug 2021
Georgiamune

Clinical-stage biotech developing immunotherapies that reprogram immune signaling to treat cancer...

Gaithersburg, United States11–50Life Sciences, Biotech
Series A·$75.0M·Aug 2023
Precision BioSciencesIPO

Clinical-stage gene editing company developing in vivo therapies using its proprietary ARCUS geno...

Durham, United States51–200Biotech, Gene Editing
Venture Round·$75.0M·Jun 2022